Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance

Clinics in Chest Medicine

Volumn 37, Issue 1, 2016, Pages 147-158

  Raju, S Vamsee ^a,b   Solomon, George M ^a   Dransfield, Mark T ^a   Rowe, Steven M ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Chronic bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis transmembrane conductance regulator; Mucociliary clearance

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; SMOKE;

ASTHMA; CHANNEL GATING; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DYSFUNCTION; DISEASE ASSOCIATION; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; HUMAN; MUCOCILIARY CLEARANCE; NONHUMAN; PASSIVE SMOKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SMOKING; SMOKING CESSATION; METABOLISM; SMOKE;

BRONCHITIS, CHRONIC; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUCOCILIARY CLEARANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE;

EID: 84959476027     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2015.11.003     Document Type: Review

References (121)

1. Ford E.S., Murphy L.B., Khavjou O., et al. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest 2015, 147(1):31-45.
2. Hoyert D.L., Xu J.Q. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012, 61(6):1-65.
3. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996, 153:1530-1535.
4. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp 2002, 248:3-12. [discussion: 12-9, 277-82].
5. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
6. Sloane P.A., Shastry S., Wilhelm A., et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 2012, 7:e39809.
7. Cantin A.M., Hanrahan J.W., Bilodeau G., et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006, 173:1139-1144.
8. Kreindler J.L., Jackson A.D., Kemp P.A., et al. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol 2005, 288:L894-L902.
9. Clunes L.A., Davies C.M., Coakley R.D., et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012, 26(2):533-545.
10. Savitski A.N., Mesaros C., Blair I.A., et al. Secondhand smoke inhibits both Cl- and K+ conductances in normal human bronchial epithelial cells. Respir Res 2009, 10:120.
11. Raju S.V., Jackson P.L., Courville C.A., et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) function. Am J Respir Crit Care Med 2013, 188(11):1321-1330.
12. Dransfield M.T., Wilhelm A.M., Flanagan B., et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 2013, 144:498-506.
13. Rab A., Rowe S.M., Raju S.V., et al. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol 2013, 305(8):L530-L541.
14. Crystal R.G. Are the smoking-induced diseases an acquired form of cystic fibrosis?. Am J Respir Crit Care Med 2013, 188:1277-1278.
15. Jain M., Goss C.H. Update in cystic fibrosis 2013. Am J Respir Crit Care Med 2014, 189:1181-1186.
16. Dolgin E. Orphan cystic fibrosis drugs find sister diseases. Nat Med 2011, 17:397.
17. Cohn J.A., Friedman K.J., Noone P.G., et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998, 339:653-658.
18. Sharer N., Schwarz M., Malone G., et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998, 339:645-652.
19. Kerem E., Hirawat S., Armoni S., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
20. Howard M.T., Anderson C.B., Fass U., et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004, 55:422-426.
21. Howard M.T., Shirts B.H., Petros L.M., et al. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 2000, 48:164-169.
22. Pignatti P.F., Bombieri C., Benetazzo M., et al. CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 1996, 58:889-892.
23. Girodon E., Cazeneuve C., Lebargy F., et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997, 5:149-155.
24. Knowles M.R., Durie P.R. What is cystic fibrosis?. N Engl J Med 2002, 347:439-442.
25. Mall M.A., Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J 2014, 44(4):1042-1054.
26. Ratjen F., Doring G. Cystic fibrosis. Lancet 2003, 361:681-689.
27. Kellermayer R., Szigeti R., Keeling K.M., et al. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol 2006, 126:229-231.
28. Varga K., Goldstein R.F., Jurkuvenaite A., et al. Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 2008, 410:555-564.
29. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. N Engl J Med 2005, 352:1992-2001.
30. Rabe K.F., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
31. Houghton A.M., Quintero P.A., Perkins D.L., et al. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 2006, 116:753-759.
32. Bartoszewski R., Rab A., Jurkuvenaite A., et al. Activation of the unfolded protein response by deltaF508 CFTR. Am J Respir Cell Mol Biol 2008, 39:448-457.
33. Saetta M., Turato G., Baraldo S., et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000, 161:1016-1021.
34. Martinez-Garcia M.A., Soler-Cataluna J.J., Donat Sanz Y., et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140:1130-1137.
35. Dransfield M.T., Washko G.R., Foreman M.G., et al. Gender differences in the severity of CT emphysema in COPD. Chest 2007, 132:464-470.
36. Hautamaki R.D., Kobayashi D.K., Senior R.M., et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277:2002-2004.
37. Lim S., Roche N., Oliver B.G., et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000, 162:1355-1360.
38. Turino G.M. Proteases in COPD: a critical pathway to injury. Chest 2007, 132:1724-1725.
39. Shifren A., Mecham R.P. The stumbling block in lung repair of emphysema: elastic fiber assembly. Proc Am Thorac Soc 2006, 3:428-433.
40. Morgan L., Pearson M., de Iongh R., et al. Scintigraphic measurement of tracheal mucus velocity in vivo. Eur Respir J 2004, 23:518-522.
41. Brown J.S., Zeman K.L., Bennett W.D. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med 2002, 166:1240-1247.
42. Moller W., Felten K., Sommerer K., et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med 2008, 177:426-432.
43. Hogg J.C., Chu F.S., Tan W.C., et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007, 176:454-459.
44. Le Gars M., Descamps D., Roussel D., et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2012, 187(2):170-179.
45. Bernard K., Rowe S.M., Fan L., et al. Inhibition of CFTR-mediated Cl- current by neutrophil elastase. Pediatr Pulmonol 2008, (Suppl):31.
46. Guimbellot J.S., Fortenberry J.A., Siegal G.P., et al. Role of oxygen availability in CFTR expression and function. Am J Respir Cell Mol Biol 2008, 39:514-521.
47. Raju S.V., Jackson P.L., Courville C.A., et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med 2013, 188:1321-1330.
48. Lambert J.A., Raju S.V., Tang L.P., et al. CFTR activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol 2013, 50(3):549-558.
49. Courville C.A., Tidwell S., Liu B., et al. Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease. Respir Res 2014, 15:25.
50. Friedlander A.L., Lynch D., Dyar L.A., et al. Phenotypes of chronic obstructive pulmonary disease. COPD 2007, 4:355-384.
51. Prescott E., Almdal T., Mikkelsen K.L., et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002, 20:539-544.
52. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005, 82:53-59.
53. Tashkin D.P., Altose M.D., Connett J.E., et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996, 153:1802-1811.
54. Han M.K., Bartholmai B., Liu L.X., et al. Clinical significance of radiologic characterizations in COPD. COPD 2009, 6:459-467.
55. Welsh M.J. Cigarette smoke inhibition of ion transport in canine tracheal epithelium. J Clin Invest 1983, 71:1614-1623.
56. Cohen N.A., Zhang S., Sharp D.B., et al. Cigarette smoke condensate inhibits transepithelial chloride transport and ciliary beat frequency. Laryngoscope 2009, 119:2269-2274.
57. Moran A.R., Norimatsu Y., Dawson D.C., et al. Aqueous cigarette smoke extract induces a voltage-dependent inhibition of CFTR expressed in Xenopus oocytes. Am J Physiol Lung Cell Mol Physiol 2014, 306:L284-L291.
58. Rasmussen J.E., Sheridan J.T., Polk W., et al. Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. J Biol Chem 2014, 289:7671-7681.
59. Maouche K., Medjber K., Zahm J.M., et al. Contribution of alpha7 nicotinic receptor to airway epithelium dysfunction under nicotine exposure. Proc Natl Acad Sci U S A 2013, 110:4099-4104.
60. Wilschanski M., Dupuis A., Ellis L., et al. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006, 174:787-794.
61. Innes A.L., Woodruff P.G., Ferrando R.E., et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006, 130:1102-1108.
62. Tamashiro E., Xiong G., Anselmo-Lima W.T., et al. Cigarette smoke exposure impairs respiratory epithelial ciliogenesis. Am J Rhinol Allergy 2009, 23:117-122.
63. Leopold P.L., O'Mahony M.J., Lian X.J., et al. Smoking is associated with shortened airway cilia. PLoS One 2009, 4:e8157.
64. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
65. Nussbaumer-Ochsner Y., Rabe K.F. Systemic manifestations of COPD. Chest 2011, 139:165-173.
66. Quinton P., Molyneux L., Ip W., et al. Beta-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012, 186(8):732-739.
67. Cote G.A., Yadav D., Slivka A., et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2010, 9(3):266-273. [quiz: e27].
68. Xie X.T., Liu Q., Wu J., et al. Impact of cigarette smoking in type 2 diabetes development. Acta Pharmacol Sin 2009, 30:784-787.
69. Yeh H.C., Duncan B.B., Schmidt M.I., et al. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. Ann Intern Med 2010, 152:10-17.
70. Gerber P.A., Locher R., Schmid B., et al. Smoking is associated with impaired long-term glucose metabolism in patients with type 1 diabetes mellitus. Nutr Metab Cardiovasc Dis 2011, 23(2):102-108.
71. Chia S.E., Lim S.T., Tay S.K. Factors associated with male infertility: a case-control study of 218 infertile and 240 fertile men. BJOG 2000, 107:55-61.
72. Uchida K., Kanematsu M., Morimitsu Y., et al. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 1998, 273:16058-16066.
73. Grafstrom R.C., Dypbukt J.M., Willey J.C., et al. Pathobiological effects of acrolein in cultured human bronchial epithelial cells. Cancer Res 1988, 48:1717-1721.
74. Jia L., Liu Z., Sun L., et al. Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: protection by (R)-alpha-lipoic acid. Invest Ophthalmol Vis Sci 2007, 48:339-348.
75. Kitaguchi Y., Taraseviciene-Stewart L., Hanaoka M., et al. Acrolein induces endoplasmic reticulum stress and causes airspace enlargement. PLoS One 2012, 7:e38038.
76. Caruso R.V., O'Connor R.J., Stephens W.E., et al. Toxic metal concentrations in cigarettes obtained from U.S. smokers in 2009: results from the International Tobacco Control (ITC) United States survey cohort. Int J Environ Res Public Health 2014, 11:202-217.
77. Rennolds J., Butler S., Maloney K., et al. Cadmium regulates the expression of the CFTR chloride channel in human airway epithelial cells. Toxicol Sci 2010, 116:349-358.
78. Hassan F., Nuovo G.J., Crawford M., et al. MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. PLoS One 2012, 7:e50837.
79. Bomberger J.M., Coutermarsh B.A., Barnaby R.L., et al. Arsenic promotes ubiquitinylation and lysosomal degradation of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels in human airway epithelial cells. J Biol Chem 2012, 287:17130-17139.
80. Mazumdar M., Christiani D.C., Biswas S.K., et al. Elevated sweat chloride levels due to arsenic toxicity. N Engl J Med 2015, 372:582-584.
81. Cantin A.M., Bilodeau G., Ouellet C., et al. Oxidant stress suppresses CFTR expression. Am J Physiol Cell Physiol 2006, 290:C262-C270.
82. Bartoszewski R., Rab A., Fu L., et al. CFTR expression regulation by the unfolded protein response. Methods Enzymol 2011, 491:3-24.
83. Ebbert J.O., Croghan I.T., Schroeder D.R., et al. Association between respiratory tract diseases and secondhand smoke exposure among never smoking flight attendants: a cross-sectional survey. Environ Health 2007, 6:28.
84. Habesoglu M., Demir K., Yumusakhuylu A.C., et al. Does passive smoking have an effect on nasal mucociliary clearance?. Otolaryngol Head Neck Surg 2012, 147:152-156.
85. Wu C.F., Feng N.H., Chong I.W., et al. Second-hand smoke and chronic bronchitis in Taiwanese women: a health-care based study. BMC Public Health 2010, 10:44.
86. Ni I., Ji C., Vij N. Second-hand cigarette smoke impairs bacterial phagocytosis in macrophages by modulating CFTR dependent lipid-rafts. PLoS One 2015, 10:e0121200.
87. Lee P.N., Chamberlain J., Alderson M.R. Relationship of passive smoking to risk of lung cancer and other smoking-associated diseases. Br J Cancer 1986, 54:97-105.
88. Lebowitz M.D. Influence of passive smoking on pulmonary function: a survey. Prev Med 1984, 13:645-655.
89. Olin J.T., Wechsler M.E. Asthma: pathogenesis and novel drugs for treatment. BMJ 2014, 349:g5517.
90. Carolan B.J., Sutherland E.R. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013, 131:627-634. [quiz: 35].
91. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725.
92. Robinson D.S., Hamid Q., Ying S., et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298-304.
93. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001, 164:S28-S38.
94. Fahy J.V., Dickey B.F. Airway mucus function and dysfunction. N Engl J Med 2010, 363:2233-2247.
95. Sheehan J.K., Richardson P.S., Fung D.C., et al. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995, 13:748-756.
96. Nakagome K., Matsushita S., Nagata M. Neutrophilic inflammation in severe asthma. Int Arch Allergy Immunol 2012, 158(Suppl 1):96-102.
97. Evans C.M., Kim K., Tuvim M.J., et al. Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009, 15:4-11.
98. Del Donno M., Bittesnich D., Chetta A., et al. The effect of inflammation on mucociliary clearance in asthma: an overview. Chest 2000, 118:1142-1149.
99. Pavia D., Bateman J.R., Sheahan N.F., et al. Tracheobronchial mucociliary clearance in asthma: impairment during remission. Thorax 1985, 40:171-175.
100. Thomas B., Rutman A., Hirst R.A., et al. Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. J Allergy Clin Immunol 2010, 126:722-729.e2.
101. Oguzulgen I.K., Kervan F., Ozis T., et al. The impact of bronchiectasis in clinical presentation of asthma. South Med J 2007, 100:468-471.
102. Sandford A. The role of CFTR mutations in asthma. Can Respir J 2012, 19:44-45.
103. Schroeder S.A., Gaughan D.M., Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995, 1:703-705.
104. Dahl M., Tybjaerg-Hansen A., Lange P., et al. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998, 351:1911-1913.
105. Dahl M., Nordestgaard B.G., Lange P., et al. Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion. J Allergy Clin Immunol 2001, 107:818-823.
106. Maurya N., Awasthi S., Dixit P. Association of CFTR gene mutation with bronchial asthma. Indian J Med Res 2012, 135:469-478.
107. Noone P.G., Knowles M.R. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2001, 2:328-332.
108. Goodwin J., Spitale N., Yaghi A., et al. Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis. Can Respir J 2012, 19:46-48.
109. Anagnostopoulou P., Riederer B., Duerr J., et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest 2012, 122:3629-3634.
110. Huang F., Zhang H., Wu M., et al. Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci U S A 2012, 109:16354-16359.
111. Skowron-zwarg M., Boland S., Caruso N., et al. Interleukin-13 interferes with CFTR and AQP5 expression and localization during human airway epithelial cell differentiation. Exp Cell Res 2007, 313:2695-2702.
112. Danahay H., Atherton H., Jones G., et al. Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002, 282:L226-L236.
113. Galietta L.J., Pagesy P., Folli C., et al. IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro. J Immunol 2002, 168:839-845.
114. Anagnostopoulou P., Dai L., Schatterny J., et al. Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice. Eur Respir J 2010, 36:1436-1447.
115. Decramer M., Rutten-van Molken M., Dekhuijzen P.N., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005, 365:1552-1560.
116. Zheng J.P., Kang J., Huang S.G., et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008, 371:2013-2018.
117. Poole P.J., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006, (3). CD001287.
118. O'Donnell A.E., Barker A.F., Ilowite J.S., et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998, 113:1329-1334.
119. Valderramas S.R., Atallah A.N. Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial. Respir Care 2009, 54:327-333.
120. Clinical Trial. NCT02135432.
121. Astrand A.B., Hemmerling M., Root J., et al. Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition. Am J Physiol Lung Cell Mol Physiol 2015, 308:L22-L32.